AllianceBernstein
ELVN icon

AllianceBernstein’s Enliven Therapeutics ELVN Stock Holding History

AllianceBernstein’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.1M Buy
896,161
+124,276
+16% +$5.28M 0.01% 729
2026
Q1 		$11.9M Buy
771,885
+735,045
+1,995% +$20.4M ﹤0.01% 1123
2025
Q4 		$567K Hold
36,840
– – ﹤0.01% 2599
2025
Q3 		$754K Hold
36,840
– – ﹤0.01% 2474
2025
Q2 		$739K Hold
36,840
– – ﹤0.01% 2447
2025
Q1 		$725K Hold
36,840
– – ﹤0.01% 2389
2024
Q4 		$829K Hold
36,840
– – ﹤0.01% 2418
2024
Q3 		$941K Hold
36,840
– – ﹤0.01% 2357
2024
Q2 		$861K Buy
36,840
+20,850
+130% +$439K ﹤0.01% 2387
2024
Q1 		$281K Buy
15,990
+1,020
+7% +$15.6K ﹤0.01% 2819
2023
Q4 		$207K Buy
14,970
+640
+4% +$7.83K ﹤0.01% 2974
2023
Q3 		$196K Buy
+14,330
New +$241K ﹤0.01% 2972

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

AllianceBernstein's ELVN Position: Q2 2026 in Review

AllianceBernstein increased its Enliven Therapeutics (ELVN) stake by 16% in Q2 2026, buying an estimated $5.28M and bringing the position to 896,161 shares worth $35.1M. The position accounts for 0.01% of the portfolio, ranked #729.

AllianceBernstein first reported a position in ELVN in Q3 2023 and has held it in 12 quarters since. 211 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • AllianceBernstein held 896,161 shares of Enliven Therapeutics worth $35.1M as of Q2 2026.
  • AllianceBernstein bought 124,276 Enliven Therapeutics shares in Q2 2026, an estimated $5.28M.
  • Enliven Therapeutics made up 0.01% of AllianceBernstein's portfolio in Q2 2026, its #729 holding.
  • AllianceBernstein first reported a position in Enliven Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 211 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.